Breaking News Instant updates and real-time market news.

KO

Coca-Cola

$45.25

0.295 (0.66%)

06:57
07/25/18
07/25
06:57
07/25/18
06:57

Coca-Cola backs FY18 comparable EPS up 8%-10%, consensus $2.08

  • 25

    Jul

KO Coca-Cola
$45.25

0.295 (0.66%)

05/17/18
LEHM
05/17/18
UPGRADE
Target $48
LEHM
Overweight
Coca-Cola upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Lauren Lieberman upgraded Coca-Cola to Overweight and raised her price target for the shares to $48 from $45. The company's transformation should drive "sustainably better growth," which should yield a higher valuation premium, Lieberman tells investors in a research note. The analyst believes Coca-Cola's "wide-ranging changes" will bring benefits to fundamentals.
05/17/18
SBSH
05/17/18
NO CHANGE
SBSH
Buy
Coca-Cola pullback brings 'compelling' valuation, says Citi
The 9% year-to-date decline in shares of Coca-Cola creates a "compelling" valuation, Citi analyst Wendy Nicholson tells investors in a research note after traveling with the company's investor relations team. The analyst attributes the weakness partly to the overall selloff of consumer staples stocks, but also partly to investor concerns about a handful of factor, including Coca-Cola's ability to achieve its financial targets both in 2018 and over the longer-term. Nicholson says her confidence in the company is up and that the share slump is not justified. She reiterates a Buy rating on Coca-Cola.
05/17/18
05/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the company's transformation should drive "sustainably better growth," which should yield a higher valuation premium. 2. Valero (VLO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Benny Wong saying recent underinvestment in refining, slippages in capacity additions and overdone concerns on long-term demand have set the stage for refining to enter a "golden age" through 2020. 3. ManTech (MANT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Edward Caso citing valuation. 4. Celanese (CE) upgraded to Buy from Neutral at UBS with analyst John Roberts saying he believes the shares are undervalued and investors do not appreciate the stability and growth in the acetyls chain and the long-term potential in Engineered Materials. 5. Canadian National (CNI) upgraded to Buy from Underperform at BofA/Merrill with analyst Ken Hoexter saying service and volume growth rebounded faster than expected and will only be aided by an improving economy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/16/18
RBCM
07/16/18
NO CHANGE
Target $75
RBCM
Outperform
Monster Beverage price hike to come November 1st, says RBC Capital
RBC Capital analyst Nik Modi says his industry sources have confirmed that Monster Beverage (MNST) intends to raise its prices by 4.0-5.5% on November 1st depending on the pack size, which would be in line with the management's indication of pricing review made at the June shareholder meeting. The analyst keeps his Outperform rating and $75 price target on Monster, adding that Coca Cola (KO), PepsiCo (PEP) and Keurig Dr Pepper (KDP) will also likely make pricing changes in response over the coming months.

TODAY'S FREE FLY STORIES

APD

Air Products

$225.97

1.455 (0.65%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Recommendations
Air Products analyst commentary  »

Air Products price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 22

    Aug

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:45
07/23/19
07/23
07:45
07/23/19
07:45
Hot Stocks
Marinus Pharmaceuticals announces data from Phase 2 Amaryllis study »

The Amaryllis Study…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:44
07/23/19
07/23
07:44
07/23/19
07:44
Hot Stocks
Marinus Pharmaceuticals announces data from Phase 2 Magnolia clinical trial »

Marinus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

07:43
07/23/19
07/23
07:43
07/23/19
07:43
Recommendations
Cadence Design analyst commentary  »

Cadence Design price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$60.62

0.77 (1.29%)

07:43
07/23/19
07/23
07:43
07/23/19
07:43
Recommendations
Itron analyst commentary  »

Canaccord sees several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:41
07/23/19
07/23
07:41
07/23/19
07:41
Hot Stocks
RedHill Biopharma continues to enroll patients in Phase 2a study of YELIVA »

The ongoing Phase 2a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FBP

First BanCorp

$10.74

-0.25 (-2.27%)

07:40
07/23/19
07/23
07:40
07/23/19
07:40
Earnings
First BanCorp reports Q2 EPS 19c, consensus 19c »

Reports Q2 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:40
07/23/19
07/23
07:40
07/23/19
07:40
Hot Stocks
RedHill Biopharma 'working toward' confirmatory Phase 3 study for BEKINDA »

RedHill is currently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

07:40
07/23/19
07/23
07:40
07/23/19
07:40
General news
Treasury Market Outlook: Treasury yields are modestly cheaper »

Treasury Market Outlook:…

ATI

Allegheny Technologies

$25.11

-0.175 (-0.69%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Earnings
Allegheny Technologies reports Q2 ex-items EPS 40c, consensus 34c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Hot Stocks
RedHill Biopharma to initiate Phase 3 study activities with RHB-204 in Q4 »

RedHill plans to initiate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

NOW

ServiceNow

$293.30

3.48 (1.20%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Recommendations
ServiceNow analyst commentary at Needham »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Hot Stocks
RedHill Biopharma says FDA meetings for RHB-104 to take place in 2H198 »

FDA meetings are planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:38
07/23/19
07/23
07:38
07/23/19
07:38
Hot Stocks
RedHill Biopharma plans U.S. launch of Talicia in 4Q19 »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

CR

Crane

$86.50

0.99 (1.16%)

, CIR

Circor

$39.83

1.17 (3.03%)

07:37
07/23/19
07/23
07:37
07/23/19
07:37
Recommendations
Crane, Circor analyst commentary  »

Crane Q2 highlighted by…

CR

Crane

$86.50

0.99 (1.16%)

CIR

Circor

$39.83

1.17 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 01

    Aug

  • 09

    Sep

  • 09

    Sep

RLGY

Realogy

$5.17

-0.08 (-1.52%)

, AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

07:37
07/23/19
07/23
07:37
07/23/19
07:37
Hot Stocks
Realogy launches TurnKey in collaboration with Amazon »

Realogy (RLGY) announced…

RLGY

Realogy

$5.17

-0.08 (-1.52%)

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

AN

AutoNation

$42.01

-0.045 (-0.11%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Recommendations
AutoNation analyst commentary  »

Stephens 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

MYOV

Myovant Sciences

$8.15

-0.25 (-2.98%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Hot Stocks
Myovant Sciences says primary efficacy endpoint met in LIBERTY 2 study »

Myovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Earnings
Kimberly-Clark sees FY19 net sales flat to down 1% y/y, consensus $18.41B »

Prior assumption was down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FB

Facebook

$202.32

3.94 (1.99%)

07:35
07/23/19
07/23
07:35
07/23/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

ARAY

Accuray

$3.91

-0.07 (-1.76%)

07:34
07/23/19
07/23
07:34
07/23/19
07:34
Hot Stocks
CNNC Accuray Medical Technology receives safety license in China »

Accuray provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

CYTK

Cytokinetics

$11.65

0.49 (4.39%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

07:34
07/23/19
07/23
07:34
07/23/19
07:34
Hot Stocks
Cytokinetics granted European orphan designation for reldesemtiv »

Cytokinetics Incorporated…

CYTK

Cytokinetics

$11.65

0.49 (4.39%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Hot Stocks
Kimberly-Clark CEO says 'we made excellent progress in the second quarter' »

CEO Mike Hsu said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LECO

Lincoln Electric

$85.18

0.39 (0.46%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Earnings
Lincoln Electric reports Q2 adjusted EPS $1.28, consensus $1.27 »

Reports Q2 revenue $777M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

LMT

Lockheed Martin

$357.57

0.675 (0.19%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Earnings
Lockheed Martin raises FY19 EPS view to $20.85-$21.15 from $20.05-$20.35 »

Consensus is $20.57.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.